Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinghua Weikang Capsule Quadruple Therapy for IgAN With H. Pylori Infection
NCT05320133Unknown
- Sponsor
- Peking University First Hospital
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Jinghuaweikang capsule in Helicobacter pylori infection (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Helicobacter pylori eradication rate at 4 weeks. Status: unknown.
02
Drugs
Jinghuaweikang capsule
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05320133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320133.